The Oligonucleotide CMO industry faces a number of challenges - Demand out pacing capacity for manufacturing, available expertise, high solvent and waste usage to name a few. The PolyPeptide Group established its OLIGO@POLYPEPTIDE division to help address some of these challenges and bring much needed medicine to patients. We discuss how PolyPeptide has leveraged its expertise in peptide manufacturing to address these challenges.